Global Blood Therapeutics
171 Oyster Point Blvd., Suite 300
South San Francisco
About Global Blood Therapeutics
GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
132 articles with Global Blood Therapeutics
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Mo...
11/13/2017Based on DSMB review, patients age 12 to 17 can now be enrolled in the phase 3 hope study.
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient With Severe and Symptomatic Anemia
The patient received the investigational agent through single-patient compassionate access.
Global Blood Therapeutics Announces Approval of First-in-Class 'Voxelotor' as Nonproprietary Name for GBT440
Voxelotor is an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen and is in clinical development for the treatment of sickle cell disease.
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
Global Blood Therapeutics Announces Presentation Of New Data Showing Positive Effect Of GBT440 On Sickle Cell Disease Patient With Variant Genotype
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers At Annual Sickle Cell Disease (SCD) Therapeutics Conference
Global Blood Therapeutics Receives Rare Pediatric Disease Designation From FDA For GBT440 For Treatment Of Sickle Cell Disease (SCD)
Global Blood Therapeutics Reports Recent Business Progress And Provides Second Quarter 2017 Financial Results
Global Blood Therapeutics Expands Ongoing Phase IIa HOPE-KIDS 1 Study Into Younger Pediatric Population
Global Blood Therapeutics Receives EMA PRIME Designation For GBT440 For The Treatment Of Sickle Cell Disease (SCD)
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development Of GBT440 In Adolescents With Sickle Cell Disease
Global Blood Therapeutics Reports Recent Business Progress And Provides First Quarter 2017 Financial Results
Global Blood Therapeutics Reports Recent Business Progress And Fourth Quarter And Year-End 2016 Financial Results
Global Blood Therapeutics Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares
Global Blood Therapeutics Announces Initiation Of Phase I Trial To Evaluate The Physiologic Effects Of GBT440 In Healthy Volunteers Under Hypoxemic Conditions
Global Blood Therapeutics Announces Publication Of Paper Describing Discovery Of GBT440 In American Chemical Society Medicinal Chemistry Letters